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Acinetobacter baumannii (American Type Culture Collection
strain 19606) acquires mutations in the pmrB gene during
the in vitro development of resistance to colistin. The
colistin-resistant strain has lower affinity for colistin,
reduced in vivo fitness (competition index, .016), and
decreased virulence, both in terms of mortality (0% lethal
dose, 6.9 vs 4.9 log colony-forming units) and survival in
a mouse model of peritoneal sepsis. These results may
explain the low incidence and dissemination of colistin
resistance in A. baumannii in clinical settings.
Acinetobacter baumannii is a gram-negative coccobacillus pro-
ducing nosocomial infections such as pneumonias, bacteremias,
urinary tract infections, surgical site infections, and meningitis,
with an attributed mortality of 7.8%–23% [1]. The emergence of
multidrug-resistant strains, impervious to most commonly used
antibiotics, has thwarted current treatment [1]. Currently, colistin
is one of the last treatments available. Despite its extensive use
against A. baumannii [2], colistin-resistant outbreaks [3] are quite
sporadic [4] when compared with the widespread dissemination
of resistance for other antibiotics, such as carbapenems [1].
Recently, variation in the levels of 35 proteins between
A. baumannii American Type Culture Collection (ATCC) strain
19606 and its in-vitro-derived colistin-resistant mutant, RC64
(colistin minimal inhibitory concentration, 2 and 64 lg/mL,
respectively), was shown by differential proteomics [5]. This
included changes in the expression of outer membrane proteins,
chaperones, translation factors, and metabolic enzymes in RC64.
In addition, this strain showed impaired in vitro fitness and
longer duplication times compared with the parental strain [5].
Colistin resistance in gram-negative bacteria is most commonly
due to decreased binding to the bacterial outer membrane because
of lipopolysaccharide remodeling that is caused by changes in
PhoPQ and PmrAB, both two-component regulatory systems,
which results in a less anionic lipid A. A recent report addressing
colistin resistance in A. baumannii strains demonstrated that
mutations in the pmrA and pmrB genes were associated with
colistin resistance [6]. Similar mutations were reported in
Salmonella enterica [7] and Pseudomonas aeruginosa [8].
In this study, our goal was to test whether the impaired in
vitro fitness described for RC64 [5] is maintained in animal
models of infection, thereby linking lower virulence to colistin
resistance, and to characterize PmrAB mutations in this
strain.
METHODS AND RESULTS
A. baumannii ATCC 19606 and its derived colistin-resistant
strain RC64 are described elsewhere [5].
Binding of dansylated polymyxin B (DPXB) to both strains was
monitored by increase of its fluorescence (kexc, 380 nm; kem, 485
nm; temperature, 37C) in bacterial suspensions in phosphate-
buffered saline (2 3 106 colony-forming units [CFUs]/mL) [9].
Lack of membrane permeabilization was tested by entrance of the
vital dye SYTOX green (kexc, 485 nm; kem, 520 nm; temperature,
37C), using 5 lmol/L cecropin A(1–7)-melittin(2–9) as a full
permeabilization control. Fluorescence microscopy was per-
formed with a Leica microscope at a concentration of 20 lg/mL,
with bacteria incubated at the highest DPXB concentration tested
after cell concentration by centrifugation (Figure 1). These results
evidenced that the lower binding of DPXB to the RC64 strain
compared with its parental ATCC 19606 strain was exclusively
due to remodeling of the outer membrane, as the existence of
additional intracellular binding sites was excluded by the absence
of uptake of the vital dye SYTOX green for both strains by co-
listin, opposite the massive influx caused by the membrane-active
CA(1–7)M(2–9), its positive control (Figure 1, inset).
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The in vitro competition index (CI) was determined from
growth cultures that consisted of (1) ATCC 19606, (2) RC64,
and (3) a mixed inoculum of equivalent CFUs from both strains.
Bacteria at a concentration of 5 3 105 CFUs/mL were grown in
20 mL of Mueller-Hinton broth (Becton Dickinson Microbiol-
ogy Systems). At 0, 12, 24, 36, 48, 60, and 72 h, 100-lL aliquots
were taken and susceptible and resistant CFUs were counted by
plating serial log dilutions on blood agar or Mueller-Hinton agar
plus colistin (32 lg/mL; Sigma Chemical). The CI was defined as
the number of RC64 CFUs recovered/number of ATCC 19606
CFUs recovered, divided by the number of RC64 CFUs
inoculated/number of ATCC 19606 CFUs inoculated. Sponta-
neous reversion of RC64 into the susceptible phenotype was
negligible during the time span of experiment.
For bacterial growth and CI experiments in an animal model
of infection, 3 groups of 12 C57BL/6 female 18–20-g mice
(University of Seville, Seville, Spain) were inoculated in-
traperitoneally with 7.9 log CFUs (the 100% lethal dose; see
below) of each strain separately and with a mixed inoculum
(50% of each strain). Subgroups of 3 mice were sacrificed at 2, 4,
8, and 24 h after inoculation. Spleens were aseptically removed,
weighed, and homogenized (Stomacher 80 homogenizer;
Tekmar), and CFUs were counted as above. To measure the CI,
9 additional mice were inoculated and processed at 24 h after
inoculation. For these experiments, approval from the Ethics
and Clinical Research Committee of the Virgen del Rocı´o
University Hospitals were obtained.
By genomic mining, A. baumannii lacks PhoPQ; thus, acti-
vation of PmrAB is likely of utmost importance for developing
colistin resistance [13]. In fact, mutations in the pmrA and pmrB
genes leading to a gain-of-function phenotype were recently
associated with colistin resistance in A. baumannii isolates [6].
We therefore characterized these genes by locus sequencing in
both ATCC 19606 and RC64 strains. To this end, genomic DNA
was obtained by resuspending a single colony in 25 lL of water
and then lysing by incubation at 100C for 10 min. After cen-
trifugation, the genomic DNA in the supernatant was used to
amplify pmrA and pmrB by polymerase chain reaction using
PmrA-B forward and PmrA-B reverse primers (PmrA-B for-
ward, ATGACAAAAATCTTGATGAT; PmrA-B reverse,
TCACGCTCTTGTTTCATGTA). Amplified products were
cloned into the pGEM-T Easy vector and sequenced using
standard methods.
The nucleotide sequence of the A. baumannii RC64 pmrB
gene was submitted to the EMBL database (GenBank accession
no. GU797240).
In the in vitro experiments (Figure 2A), the growth rates of
the 3 cultures were similar after 24 h, including in the experi-
ments in which strains were grown together (CI, 1.05). However,
at 72 h, the growth rate of RC64 was lower than that of ATCC
19606 (1 log difference), with a CI of .09. In the in vivo ex-
periments, the CFUs in spleens from animals infected with ei-
ther ATCC 19606 or RC64 (Figure 2B) differed by 1 log at 24 h;
the difference increased to 2 log in the mixed infection group
(CI, .016). This result suggests that in vivo conditions enhance
the difference in fitness between the strains. Whereas the lower
in vitro fitness of RC64 required at least 3 d to reach significance,
in the in vivo experiments, only 1 d was required. Competition
Figure 1. Differential binding of dansyl polymyxin B (DPXB) to bacterial cells of American Type Culture Collection (ATCC) strain 19606 and colistin-
resistant mutant strain RC64 of Acinetobacter baumannii. A, Variation of DPXB binding with concentration bacterial density of 2 3 106 colony-forming
units (CFUs)/mL (diamonds and dotted line, ATCC 19606; filled circles and solid line, RC64). The inset shows the inner membrane permeabilization as
assessed by entrance of the vital dye SYTOX green, using 5 lmol/L of CA(1–7)M(2–9) as a positive control (100% permeabilization; black bars, ATCC
19606; white bars, RC64). B, Fluorescence microscopy of ATCC 19606 cells incubated with DPXB (20 lg/mL). C, Fluorescence microscopy of RC64 cells
incubated with DPXB (20 lg/mL).
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for nutrients and the stress produced by effector systems of the
innate immune response in vivo may heighten the impaired
metabolic efficiency and capacity to cope with stress for RC64
[5].
The virulence of both strains was further compared in terms
of mortality and lethal dose (Reed and Muench method) [10], as
well as by measuring the survival time of the infected mice. For
each strain, groups of 10 animals were infected intraperitoneally
with an inoculum of 250 lL starting at 8.5 log CFUs/mL, and
then the inocula were serially 10-fold diluted until 100% survival
was attained. Bacteria were mixed with porcine mucin (Sigma)
at 5% (weight per volume) final concentration prior to in-
oculation. Mortality with the ATCC 19606 strain at an inoculum
of 8.5, 7.5, 6.5, and 5.5 log CFUs/mL was 100%, 80%, 20%, and
0%, respectively. With the RC64 strain, 100% mortality was
observed with an inoculum of 8.5 log CFUs/mL, but no mor-
tality was achieved with the rest of inocula. With these results,
lethal doses of 100% (LD100), 50% (LD50), and 0% (LD0) were
7.9, 6.4, and 4.9 log CFUs, respectively, for ATCC 19606 and 7.9,
7.4, and 6.9 log CFUs, respectively, for RC64.
In animals inoculated with LD100 (7.9 log CFUs), the mean
time to death for RC64 was twice that for ATCC 19606 (mean
time to death [6 SD], 38.4 6 9.3 h vs 20.0 6 0.0 h; P , .001;
Student t test), (Figure 2C). This lower virulence associated
with colistin resistance has also been described for S. enterica
[11]. In our experiments, the lower virulence of RC64 is in
tune with the lower expression of metabolic proteins and of
the OmpA porin [5], which is involved in Acinetobacter spe-
cies virulence [12].
In the resistant strain RC64, no mutations were found in
pmrA, the response regulator element. In pmrB, the sensor
kinase, mutations were found at positions R134C and A227V.
The latter was previously reported in a colistin-resistant A.
baumannii strain [6] and mapped inside the conserved histidine
box motif [14] adjacent to H228, a putative acceptor for the
phosphoryl group, and to A226, which is involved in histidine
kinase dimerization [14]. A similar mutation in P. aeruginosa is
also associated with a polymyxin-resistant phenotype [8]. The
other mutation, R134C, was not previously described. This
mutation is presumably not innocuous because of the chemical
nature of the new side group and also because this arginine was
conserved throughout the species of the genus Acinetobacter.
DISCUSSION
The lower in vivo bacterial fitness and decreased virulence of
colistin-resistant A. baumannii showed in this study may suggest
that the extensive use of colistin for the treatment of
A. baumannii infections is a safe and consistently effective
strategy from an evolutionary point of view. However, caution
must be stressed in this sense. Many resistance mutations are
initially maladaptive, but for most of these, compensatory mu-
tations can ameliorate the fitness deficit. Ultimately, this process
can lead to fixation of resistance mutations, even those with
a high initial fitness cost. Constant exposure to the initial se-
lective agent, such as colistin in A. baumannii, may prevent
reversion of resistance, thus providing the time required for the
resistant strain to re-adapt and for the resistance to thereby
Figure 2. In vitro (A) and in vivo (B ) growth of American Type Culture Collection (ATCC) strain 19606 and colistin-resistant mutant strain RC64 of
Acinetobacter baumannii, separately and in competition, and time of survival (evaluated every 4 h) with the 100% lethal dose of A. baumannii strains
ATCC 19606 and RC64 (C ). CFU, colony-forming unit.
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become fixed. Once this process is complete, reversion is very
unlikely and resistance can spread without further selection, as
occurs with Mycobacterium tuberculosis [15]. Thus, if compen-
satory mutations are possible, but simply have yet to occur, this
could actually be the path by which colistin could be rendered
useless for such infections, as extended use could provide the
exact environment in which compensatory mutations could
arise, become fixed, and then allow the spread and fixation of
resistance mutations.
In summary, we have shown for the first time (to our knowl-
edge) that resistance to colistin in A. baumannii is associated
with lower in vivo bacterial fitness and decreased virulence,
similar to other gram-negative pathogens. This may account for
the low incidence of colistin resistance in the clinical setting.
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